Navigation Links
Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
Date:9/8/2008

of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Kurt Leutzinger

CFO

Kurt.leutzinger@pharmasset.com

Office: 609-613-4110

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that the final results of the third and fourth cohorts of the 4-week Phase I clinical trial evaluating R7128 will be materially different from the preliminary results, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from t
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
2. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
3. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
4. Pharmasset Joins Russell 3000 Index
5. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
6. Pharmasset Selected to Join the NASDAQ Biotechnology Index
7. Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th
8. Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
9. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
10. Pharmasset Receives $10 Million of Working Capital
11. Pharmasset Appoints Herbert J. Conrad as a Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Mass. , July 30, 2014  Decision ... pharmacy and medical directors in the ... drivers of biosimilar market penetration will be the ... organizations (MCOs) and the expected lower cost to ... for biosimilars that meet their pricing expectations in ...
(Date:7/30/2014)... 30, 2014 While administrative claims ... services research for a relatively long period of ... regarding the use of these ‘big data’ for ... By combining today’s powerful computer technology with the ... ‘big data’ holds significant promise for identifying optimal ...
(Date:7/30/2014)... July 30, 2014 With the ... of personal health expenditure as well as the ... system, China diagnostic reagent industry has been developing ... 90%. In 2013, Chinese in vitro diagnostics market ... came from in vitro diagnostic reagents. , ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Yuma ... facility and complementary therapies brings comprehensive cancer care ... state-of-the-art Yuma Regional Cancer Center has officially opened. ... the program includes services such as open, semi-private ... therapy, American Cancer Society Resource Center, hematology, rehabilitation ...
Breaking Biology Technology:Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2
... Pasteuria Bioscience announced that it has received registration ... Pasteuria usgae . This is a critical step towards ... bacteria prevalent in soil that have long been recognized as ... , "We,re very pleased to receive this EPA registration," ...
... STOCKHOLM, June 8 Diamyd Medical reported today,that the company ... to include children with type 1 diabetes from 10 years,of ... vaccine Diamyd(R). , (Logo: http://www.newscom.com/cgi-bin/prnh/20080314/297194 ... conducting two parallel phase III studies, one in,Europe and one ...
... Through One Year , , HERZLIYA, Israel and SKILLMAN, ... U.S. Food and Drug Administration (FDA) approved a labeling supplement ... EVOLENCE(R), a collagen-based dermal filler for the correction of moderate ... , , To view the Multimedia News Release, go ...
Cached Biology Technology:Pasteuria Bioscience Receives EPA Registration for Nematode Control 2Diamyd(R) Phase III Study Approved for Younger Patients in the US 2Photos: FDA Approves 12-Month Labeling Update for EVOLENCE(R) Collagen-Based Facial Filler 2Photos: FDA Approves 12-Month Labeling Update for EVOLENCE(R) Collagen-Based Facial Filler 3Photos: FDA Approves 12-Month Labeling Update for EVOLENCE(R) Collagen-Based Facial Filler 4
(Date:7/30/2014)... scientists unveiled the first high-resolution map of the ... country of Per. The new and improved methodology ... change for future market-based carbon economies. The ... ecological diversity and it provides the critical input ... conservation, land use, and enforcement purposes. The technique ...
(Date:7/29/2014)... of Bristol,s Nutrition and Behaviour Unit (NBU) has looked ... planning meals. , The research, to be presented at ... (SSIB 2014) in Seattle, USA this week [29 July ... team was led by Professor Jeff Brunstrom, and is ... part of a Biotechnology and Biological Sciences Research Council ...
(Date:7/29/2014)... the climate warms and sea ice retreats, the North ... of increasingly open water which is predicted to extend ... this century. Storms thus have the potential to create ... new and unpredictable element to the region. , A University ... in the middle of the Arctic Ocean, and detected ...
Breaking Biology News(10 mins):Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3Huge waves measured for first time in Arctic Ocean 2Huge waves measured for first time in Arctic Ocean 3
... engineers at Purdue University have developed a new method ... and they are proposing the creation of mobile processing ... fuels. "What,s important is that you can ... chips, switch grass, corn stover, rice husks, wheat straw ...
... tract is a teeming mass of hundreds of types of ... help us digest food and keep bad bacteria in check. ... receptor is a key player amid the gut bacteria ... helping to govern their activity, responding to their cues, and ...
... calling on policymakers to encourage the transition from coal-based electricity ... carbon tax. Such a mechanism would help limit carbon ... Change Conference in Copenhagen last December, the United States pledged ... by 17 percent by 2020. Dagobert Brito, the ...
Cached Biology News:New biofuels processing method for mobile facilities 2New biofuels processing method for mobile facilities 3Amid the murk of 'gut flora,' vitamin D receptor emerges as a key player 2Amid the murk of 'gut flora,' vitamin D receptor emerges as a key player 3Researchers calculate the cost of CO2 emissions, call for carbon tax 2
... (1995) This volume provides excellent ... for the study of major HIV proteins ... ribonuclease H, integrase and protease. Expression of ... Tat and Rev assays; HIV/CD4 interactions; transient ...
Monkey IL-2 ELISPOT Kit with white/opague microtiter plates...
Tachykinin (H-2)...
Human GATA-2 Affinity Purified Polyclonal Ab...
Biology Products: